Does Lurbinectedin Cross the Placenta?
Lurbinectedin, a chemotherapy agent sold as Zepzelca for small cell lung cancer, is category D under old FDA pregnancy classifications, indicating positive evidence of human fetal risk based on animal studies and limited human data. Preclinical studies in pregnant rats and rabbits at doses similar to human equivalents showed embryo-fetal toxicity, including reduced fetal weight, skeletal variations, and increased post-implantation loss, suggesting placental transfer occurs.[1][2]
No direct human placental transfer studies exist, but its low molecular weight (784 Da) and moderate protein binding (around 99%) allow diffusion across the placenta, especially in the second and third trimesters when the barrier thins. Alkylating-like agents like lurbinectedin typically cross readily, as seen with similar drugs (e.g., cyclophosphamide).[3]
What Do Animal Studies Show?
In rats dosed intravenously at 0.4 mg/kg (about human exposure), fetuses had anomalies; in rabbits at 0.2 mg/kg, resorption rates rose. These effects imply maternal-fetal transfer, as unbound drug reaches fetal circulation. No genotoxicity was seen in non-pregnant models, but fetotoxicity points to placental permeability.[1][4]
Human Pregnancy Data and Warnings
Post-marketing reports and the Zepzelca label advise against use in pregnancy due to fetal harm risk. One case series noted miscarriage after first-trimester exposure, but transfer wasn't measured directly. Women of childbearing potential must use contraception during treatment and for 6 months after.[2][5]
Clinical Recommendations for Pregnant Patients
Discontinue immediately if pregnancy occurs; consider termination counseling. No antidote exists; monitor fetal development via ultrasound if exposure happens early. Breastfeeding is contraindicated due to excretion in milk.[2]
How Does It Compare to Similar Chemotherapy Drugs?
| Drug | Placental Transfer | Fetal Risk Evidence |
|------|---------------------|---------------------|
| Lurbinectedin | Likely (inferred from animal data, pharmacokinetics) | High (teratogenic in animals) [1] |
| Cisplatin | Yes (measured in amniotic fluid) | High ototoxicity, nephrotoxicity [6] |
| Doxorubicin | Yes (fetal heart exposure) | Cardiomyopathy risk [7] |
| Cyclophosphamide | Yes (rapid equilibrium) | Limb defects, growth restriction [3] |
Regulatory and Patent Context
Lurbinectedin holds U.S. patents until 2031-2034 (e.g., US 9,346,832 for composition).[8] No pregnancy-specific patents, but EMA/FDA labels mandate fetal risk warnings. For full patent details, see DrugPatentWatch.com.
Sources
[1]: FDA Zepzelca Label
[2]: Drugs.com Pregnancy Warnings
[3]: Clin Pharmacokinet 2018;57:1397
[4]: Eur J Cancer 2020;129:70
[5]: FDA REMS Program
[6]: J Clin Oncol 2004;22:2817
[7]: Cancer Treat Rev 2016;45:13
[8]: DrugPatentWatch.com - Zepzelca